title: The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
abstract: OBJECTIVE
  To classify MUC1 according to five predefined expression patterns in ductal carcinoma in situ (DCIS) and related clinicopathological parameters, coexpression of other biological markers and prognosis.
  
  
  RESULTS
  With a manual tissue arrayer, 92% (n = 80) of the 87 DCIS samples were successfully targeted. Immunohistochemistry was carried out for MUC1, oestrogen receptor (ER), progesterone receptor (PR), Her2/Neu, p53 and cyclin D1. Entire membrane expression was related to Her2/neu negativity (P =0.042). Apical membrane expression was associated with low grade (P = 0.027), Her2/neu negativity (P = 0.014) and PR positivity (P = 0.005). Focal cytoplasmic expression was related to high grade (P = 0.006). Diffuse cytoplasmic expression was associated with high grade (P = 0.004), large tumour size (P = 0.046), Her2/neu positivity (P =0.042) and cyclin D1 positivity (P = 0.002). On the basis of these analyses the four patterns were reclassified as membranous or cytoplasmic expression. On multivariate analysis, cytoplasmic MUC1 expression (hazard ratio 8.5, 95% confidence interval 1.0, 73.0; P = 0.04) was the only independent predictor of local recurrence.
  
  
  CONCLUSIONS
  Four patterns of MUC1 expression are recognized in DCIS that suggest a relationship to functional differentiation and can be simplified into two types that are clinically relevant and could therefore be helpful in the distinction between different subgroups of DCIS.
authors.affiliation: Department of Surgical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
authors.forename: M A J
authors.initials: MA
authors.lastname: de Roos
authors.forename: B
authors.initials: B
authors.lastname: van der Vegt
authors.forename: J L
authors.initials: JL
authors.lastname: Peterse
authors.forename: C
authors.initials: C
authors.lastname: Patriarca
authors.forename: J
authors.initials: J
authors.lastname: de Vries
authors.forename: G H
authors.initials: GH
authors.lastname: de Bock
authors.forename: J
authors.initials: J
authors.lastname: Wesseling
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology* / Q000601:surgery; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000378:metabolism* / Q000473:pathology* / Q000601:surgery; D056741:Cyclin D; D016213:Cyclins / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015412:Mastectomy, Segmental; D046228:Microarray Analysis; D008875:Middle Aged; D018396:Mucin-1 / Q000378:metabolism*; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D056741:Cyclin D; D016213:Cyclins; D018396:Mucin-1; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; C495901:TP53 protein, human; C508053:ERBB2 protein, human